Cladribine News and Research

RSS
BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

New Sermo Event Report assesses physicians' perception of multiple sclerosis drugs

New Sermo Event Report assesses physicians' perception of multiple sclerosis drugs

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Refuse to file letter on NDA for Cladribine Tablets issued to EMD Serono

Refuse to file letter on NDA for Cladribine Tablets issued to EMD Serono

EMD Serono submits NDA for Cladribine Tablets in the U.S.

EMD Serono submits NDA for Cladribine Tablets in the U.S.

Neurologists recommend oral cladribine for treating multiple sclerosis

Neurologists recommend oral cladribine for treating multiple sclerosis

Giving children access to drug clinical trials is crucial, clofarabine approval shows

Giving children access to drug clinical trials is crucial, clofarabine approval shows

FDA approval for Cladribine to treat active Hairy Cell Leukemia

FDA approval for Cladribine to treat active Hairy Cell Leukemia

Cladribine Targeted to Become First Oral Therapy for Multiple Sclerosis

Cladribine Targeted to Become First Oral Therapy for Multiple Sclerosis

New therapy for multiple sclerosis sufferers

New therapy for multiple sclerosis sufferers